A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT ID: NCT06047457
Last Updated: 2025-12-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
714 participants
INTERVENTIONAL
2023-09-29
2026-12-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound.
Episodic Migraine is defined as having less than 15 days of headache a month with at least 6 days with migraine headaches.
Migraines are caused by a series of events which cause the brain to get stimulated / activated, which results in the release of chemicals that cause pain.
Dysport® is a formulation of Botulinum toxin type A (BoNT-A), a medication that stops the release of these chemical messengers.
The study will consist of 3 periods:
1. A 'screening period' of 6 to 12 weeks to assess whether the participant can take part to the study and requires 1 visit.
2. A first Treatment Phase of 24 weeks. On Day 1 and at Week 12 of the first Treatment Phase, participants will receive injections into various muscles across the head, neck, face and shoulders.
The injections will contain either a dose "A" or a dose ''B'' of Dysport® or a placebo (an inactive substance or treatment that looks the same as, and is given in the same way as, an active drug or intervention/treatment being studied).
Participants will make 4 visits to the clinic in person and have 4 remote (online) visits.
3. A second Treatment Phase of 24 weeks (extension phase). At Week 24 and at Week 36, all participants will get Dysport® (dose "A" or dose "B").
There will be 3 in person visits and 4 remote visits.
Participants will need to complete an e-diary and questionnaires throughout the study.
Participants will undergo blood samplings, urine collections, physical examinations, and clinical evaluations. They may continue some other medications, but the details need to be recorded.
The total study duration for a participant will be up to 60 weeks (approx. 14 months).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444
Efficacy and Safety Study of Dysport® Used for Migraine Prophylaxis
NCT00301665
Dysport® In Migraine Without Aura Prophylaxis : DIMWAP Study
NCT00258609
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
NCT05028569
The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents
NCT00195741
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dysport® dose "A"
Participant will receive four treatment cycles, each separated by an interval of 12 weeks.
Double-blind placebo-controlled (DBPC) Phase: Dysport® dose "A" administered intramuscularly on Day 1 and Week 12.
Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Botulinum toxin type A
Dose "A" U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Dysport® dose "B"
Participant will receive four treatment cycles, each separated by an interval of 12 weeks.
DBPC Phase: Dysport® dose "B" administered intramuscularly on Day 1 and Week 12.
Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48)
Botulinum toxin type A
Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Placebo - Dysport dose "A"
Participant will receive four treatment cycles, each separated by an interval of 12 weeks.
DBPC Phase: Placebo dose "A" administered intramuscularly on Day 1 and Week 12.
Extension Phase: Dysport® dose "A" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).
Placebo
"0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.
Botulinum toxin type A
Dose "A" U/I, IM on Week 24 and Week 36 with a total of 2 injections.
Placebo - Dysport dose "B"
Participant will receive four treatment cycles, each separated by an interval of 12 weeks.
DBPC Phase: Placebo dose "B" administered intramuscularly on Day 1 and Week 12.
Extension Phase: Dysport® dose "B" administered intramuscularly at Week 24 and Week 36 (final follow-up at Week 48).
Placebo
"0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.
Botulinum toxin type A
Dose "B" U/I, IM on Week 24 and Week 36 with a total of 2 injections.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Botulinum toxin type A
Dose "A" U /Injection (U/I) , Intramuscular (IM) on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Botulinum toxin type A
Dose "B" U/I, IM on every 12 weeks during a period of 36 weeks with a total of 4 injections.
Placebo
"0" U/I, IM on Day 1 and Week 12 with a total of 2 injections.
Botulinum toxin type A
Dose "A" U/I, IM on Week 24 and Week 36 with a total of 2 injections.
Botulinum toxin type A
Dose "B" U/I, IM on Week 24 and Week 36 with a total of 2 injections.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has a diagnosis for more than 12 months, prior to screening visit, of migraine with aura or migraine without aura according to the International Classification of Headache Disorders definition and diagnostic criteria
* Migraine onset occurred when participant was \<50 years of age.
* Has baseline number of monthly headache days (MHD) of \<15 and baseline number of monthly migraine days (MMD) of ≥6, using eDiary data collected during the 4 weeks nearest to randomisation on Day 1 (but prior to randomisation).
* Has baseline number of valid diary days ≥22 days collected during the 4 weeks nearest to randomisation on Day 1.
* Participant must have previously used, or is currently using, preventive treatment for migraine (pharmacological) (i.e. non-naïve) prior to start of screening eDiary
Exclusion Criteria
* Headache attributed to another disorder (e.g. secondary headaches), except medication overuse headache, which is permitted.
* Use of any of the following medications in the specified timeframe prior to start of the screening daily headache eDiary:
* a. Within 24 weeks
* i. Botulinum toxin for migraine (or for any other medical/aesthetic reason within 16 weeks)
* b. Within 12 weeks
* i. CGRP antagonists (monoclonal antibody or gepant) for preventive treatment of migraine (acute treatment of headache/migraine with a gepant is permitted, but limited to no more than 6 days per month (i.e. 6 days per each 4-week period with gepant intake))
* ii. Cannabinol or other types of cannabinoids
* c. Within 4 weeks
* i. Anaesthetic or steroid injection in any region targeted for injection with study intervention
* ii. Use of medical device to treat migraine (e.g. non-invasive neuromodulation therapies such as nerve stimulation (gammaCore), transcranial magnetic stimulation (cephaly), external trigeminal nerve stimulation, transcutaneous electrical nerve stimulation, and peripheral neuroelectrical stimulation)
* iii. Other interventions for migraine assessed to interfere with study evaluations (e.g. acupuncture in head and neck region, cranial traction, nociceptive trigeminal inhibition, occipital nerve block treatments, and dental splints for headache) iv. Use of opioids or barbiturates for more than 2 days/month.
Note: participants are permitted to take one concomitant migraine preventative treatment (not listed above); however, the dose of this medication should be stable for ≥3 months before start of the screening eDiary.
• Known history of treatment failure to more than four medications prescribed for the prevention of migraine (two of which have different mechanisms of action) or known history of treatment failure to botulinum toxin prescribed for the prevention of migraine.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Research Associates
Birmingham, Alabama, United States
CCT Research
Phoenix, Arizona, United States
HonorHealth Neurology
Scottsdale, Arizona, United States
Hope Clinical Research, LLC
Canoga Park, California, United States
Axiom Research LLC
Colton, California, United States
Fullerton Neurological Center
Fullerton, California, United States
Neurology Center of North Orange County
Fullerton, California, United States
SDS Clinical Trials
Orange, California, United States
Alliance Clinical San Diego (Acclaim Clinical Research)
San Diego, California, United States
The Los Angeles Headache Center
Savannah, California, United States
Yale University School of Medicine
East Hartford, Connecticut, United States
Hasbani Neurology
New Haven, Connecticut, United States
Visionary Investigators Network (VIN)
Aventura, Florida, United States
Velocity Clinical Research - Hallandale Beach
Hallandale, Florida, United States
AGA Clinical Trials
Hialeah, Florida, United States
Infinity Clinical Research, LLC
Hollywood, Florida, United States
Clinical Neuroscience Solutions Healthcare, Inc (CNS Healthcare, INC)
Jacksonville, Florida, United States
840042
Miami, Florida, United States
Quantum Clinical Trials
Miami Beach, Florida, United States
Clinical Neuroscience Solutions, Inc ((CNS Healthcare) - Psychiatry)
Orlando, Florida, United States
Guardian Angel Research Center
Tampa, Florida, United States
Boston Clinical Trials Inc
Winter Park, Florida, United States
Conquest Research
Winter Park, Florida, United States
CenExel iResearch Atlanta, LLC
Decatur, Georgia, United States
Cedar Crosse Research Center
Chicago, Illinois, United States
Chicago Headache Center & Research Institute
Chicago, Illinois, United States
Robbins Headache Clinic
Riverwoods, Illinois, United States
MD Fort Wayne Neurological Center
Fort Wayne, Indiana, United States
Comprehensive Neurology Services
Frederick, Maryland, United States
Boston Clinical Trials Inc
Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center - Arnold Pain Management
Brookline, Massachusetts, United States
Neurology Center of NE,PC - Neurology
Foxborough, Massachusetts, United States
Lone Star Neurology,
Westborough, Massachusetts, United States
New England Regional Headache Center, Inc.
Worcester, Massachusetts, United States
Quest Research Institute
Farmington Hills, Michigan, United States
Minneapolis Clinic of Neurology
Burnsville, Minnesota, United States
Clinical Research Professionals
Chesterfield, Missouri, United States
M3 Wake Research - Las Vegas Wellness Way
Las Vegas, Nevada, United States
Alliance Clinical Las Vegas (Excel Clinical Research)
Las Vegas, Nevada, United States
SPRI Clinical Trials, LLC
Brooklyn, New York, United States
Nuvance Health Medical Practice
Poughkeepsie, New York, United States
Rochester Clinical Research
Rochester, New York, United States
Asheville Neurology Specialists
Asheville, North Carolina, United States
Headache Wellness Center
Greensboro, North Carolina, United States
Blue Sky MD
Hendersonville, North Carolina, United States
Headache Center of Hope
Cincinnati, Ohio, United States
OrthoNeuro
New Albany, Ohio, United States
Helios Clinical Research
Wooster, Ohio, United States
Suburban Research Associates
Media, Pennsylvania, United States
Thomas Jefferson University Hospital - Jefferson Hospital for Neuroscience - Jefferson Neurology Associates - Neurology
Philadelphia, Pennsylvania, United States
Coastal Carolina Research Center - North Charleston
North Charleston, South Carolina, United States
Neurology Clinic, PC
Cordova, Tennessee, United States
KCA Neurology, PLLC
Franklin, Tennessee, United States
Helios Clinical Research LLC (Helios CR, Inc. Jackson TN)
Jackson, Tennessee, United States
Herzog, Steven MD
Dallas, Texas, United States
Zenos Clinical Research
Dallas, Texas, United States
Lone Star Neurology
Frisco, Texas, United States
Clinical Trial Network
Houston, Texas, United States
Research Your Health
Plano, Texas, United States
J. Lewis Research Inc.-Foothill
Salt Lake City, Utah, United States
Metrodora Institute
West Valley City, Utah, United States
Inova Medical Group - Neurology
Fairfax, Virginia, United States
MedStar Health - Department of Neurology
Columbia, Washington, United States
Frontier Clinical Research, LLC
Kingwood, West Virginia, United States
BCN Research, LLC
Greenfield, Wisconsin, United States
Neuroscience Group of Northeast Wisconsin-Neenah
Neenah, Wisconsin, United States
Genge Partners Inc.
Montreal, , Canada
CARe Clinic-Calgary
Red Deer, , Canada
Bluewater Clinical Research Group Inc.
Sarnia, , Canada
Neurologie Brno s.r.o.
Brno, , Czechia
Pratia Brno s.r.o.
Brno, , Czechia
NEUROHK s.r.o.
Choceň, , Czechia
Nemocnice Jihlava, p.o.
Jihlava, , Czechia
Fakultni nemocnice Ostrava
Ostrava, , Czechia
Axon Clinical, s.r.o.
Prague, , Czechia
DADO MEDICAL s.r.o.
Prague, , Czechia
Fakultni Thomayerova nemocnice
Prague, , Czechia
Institut neuropsychiatricke pece
Prague, , Czechia
CHRU d'Amiens
Amiens, , France
CHU Nimes - Hôpital Caremeau
Nîmes, , France
Assistance Publique-Hopitaux de Paris (AP-HP) - Unite de Recherche Clinique Saint-Louis Lariboisere-Ferd Widal
Paris, , France
Ltd "Health"
Batumi, , Georgia
"Pineo Medical Ecosystem" LTD
Tbilisi, , Georgia
LTD New Hospitals
Tbilisi, , Georgia
LTD S.Khechinashvili University Hospital
Tbilisi, , Georgia
Multprofil Clinic Consilium Medulla
Tbilisi, , Georgia
ISR-GEO Med Res Clin Healthycore
Tbilisi, , Georgia
Charité - Universitätsmedizin Berlin KöR
Berlin, , Germany
Emovis GmbH
Berlin, , Germany
Universitätsmedizin Greifswald
Greifswald, , Germany
Kopfschmerzzentrum Frankfurt am Main
Hessen, , Germany
LMU - Klinikum der Universität München - Campus Grosshadern
München, , Germany
Centrum Medyczne Neuromed Pawel Lisewski
Bydgoszcz, , Poland
Synexus Polska Sp. z o.o.
Gdynia, , Poland
Centrum Medyczne Pratia Katowice
Katowice, , Poland
Krakowska Akademia Neurologii Sp. z o.o.
Krakow, , Poland
Krakowskie Centrum MedyczneSp.z o.o
Krakow, , Poland
Pratia MCM Krakow
Krakow, , Poland
Indywidualna Praktyka Lekarska dr hab. med. Anna Szczepanska-Szerej
Lublin, , Poland
Instytut Zdrowia Dr Boczarska-Jedynak Sp. z o.o. S.K.
Oświęcim, , Poland
Hospital Universitari Vall D Hebron
Barcelona, , Spain
Complejo Hospitalario Ruber Juan Bravo
Madrid, , Spain
Hospital Universitario 12 De Octubre
Madrid, , Spain
Hospital Universitario Regional De Malaga
Málaga, , Spain
Hospital Universitario y Politécnico La Fe
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-504839-40-00
Identifier Type: CTIS
Identifier Source: secondary_id
CLIN-52120-464
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.